Iain J. Mulford

Most-cited papers

1. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

   Sana Raoof, Iain J. Mulford, Heidie Frisco-Cabanos, Varuna Nangia +22 more

   2019Oncogene189 citations Open access

   Semantic Scholar

   Save

2. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

   Sunkyu Kim, R. Tiedt, Alice T. Loo, Thomas Horn +13 more

   2018OncoTarget80 citations Open access

   Semantic Scholar

   Save

3. Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model

   G. Argast, Joseph S. Krueger, S. Thomson, Isabela Sujka-Kwok +13 more

   2011Clinical and Experimental Metastasis74 citations

   Semantic Scholar

   Save

4. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

   H. Wang, Iain J. Mulford, F. Sharp, Jinsheng Liang +16 more

   2021Cancer Research47 citations

   Semantic Scholar

   Save

5. Cooperative Signaling between Oncostatin M, Hepatocyte Growth Factor and Transforming Growth Factor-β Enhances Epithelial to Mesenchymal Transition in Lung and Pancreatic Tumor Models

   G. Argast, Peter Mercado, Iain J. Mulford, M. O'Connor +5 more

   2010Cells Tissues Organs29 citations

   Semantic Scholar

   Save

6. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

   R. Tiedt, Frederick J. King, C. Stamm, M. Niederst +17 more

   2023Cell Reports12 citations Open access

   Semantic Scholar

   Save

7. Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

   Sunkyu Kim, R. Tiedt, Alice T. Loo, Thomas Horn +13 more

   2020OncoTarget4 citations Open access

   Semantic Scholar

   Save

8. Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

   Hui-Qin Wang, Jinsheng Liang, Iain J. Mulford, F. Sharp +13 more

   2018Clinical research3 citations

   Semantic Scholar

   Save

9. BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma

   Jin-Xiu Li, Mary L. Nelson, Li Li, Xiao-Bo Xia +31 more

   2026Cancer Research1 citations Open access

   Semantic Scholar

   Save

10. Abstract 3499: BRD9 functions as a negative regulator of GBAF in synovial sarcoma

    Jin-Xiu Li, Mary L. Nelson, Li Li, Xiao-Bo Xia +27 more

    2026Cancer Research0 citations

    Semantic Scholar

    Save

11. Abstract 257: Targeting AML through apoptosis activation using Bcl-2/Mcl-1 or Bcl-2/Hdm2 inhibitor combination therapies

    Youzhen Wang, S. Qui, Sneha Sanghavi, Iain J. Mulford +15 more

    2019Experimental and Molecular Therapeutics0 citations

    Semantic Scholar

    Save

12. Abstract 1463: Pharmacological impact of epithelial-mesenchymal plasticity in the H358 lung tumor model

    G. Argast, Peter Mercado, M. O'Connor, Iain J. Mulford +4 more

    20100 citations

    Semantic Scholar

    Save

13. Role of PAK1 and PAK2 kinases in Snail phosphorylation and in the epithelial-mesenchymal transition

    S. Shaaban, M. O'Connor, Iain J. Mulford, S. Thomson +2 more

    20070 citations

    Semantic Scholar

    Save